Access TOC
Download Data
December 2024
The global eltrombopag drugs market was estimated at US$ 2.28 billion in 2023 and is projected to grow to US$ 5.28 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.94% from 2024 to 2034. The demand for eltrombopag is increasing due increasing demand in cancer treatment. During cancer treatment, the number of platelets decreases, due to which eltrombopag is used.
Unlock Infinite Advantages: Subscribe to Annual Membership
Thrombocytopenia, or reduced platelets in the blood, is a blood condition known as chronic immune thrombocytopenia (ITP), which is treated with eltrombopag. This medication is used after a splenectomy or surgery to remove the spleen when other medications, such as immunoglobulin or steroids, have not been effective enough. Eltrombopag is also used in conjunction with interferon therapy to treat thrombocytopenia in individuals with chronic hepatitis C.
In 2023, Novartis, whose eltrombopag medications are marketed under the Promacta brand, made $563 million (up 4% cc) annually. Due to severe aplastic anemia and the rising usage of chronic ITP, it grew mostly in the United States.
Approximately 80% of all occurrences of leukemia are of this kind, which is the most prevalent among adults. It is essential to comprehend the worldwide epidemiology of AML in order to evaluate treatment demand and guide the distribution of healthcare resources. 33% of all new cancer cases and 31% of all cancer deaths in children ages 0–14 are caused by childhood leukemia (CL), which is a serious worldwide problem. Thrombocytopenia during induction treatment is common in patients with acute myeloid leukemia. An oral thrombopoietin receptor agonist called eltrombopag works similarly to natural thrombopoietin in promoting platelet formation.
For instance,
Emergency circumstances may arise due to the moderate to severe adverse effects of the medications. Eltrombopag oral pills may also interact with a number of other drugs. Different consequences might result from different interactions. Some, for example, might enhance the adverse effects of a medication, while others can affect how effectively it works. There's a black box warning for this medicine. The Food and Drug Administration (FDA) has issued its most severe warning. Doctors and patients are warned about potentially harmful side effects of the medication with a black box warning.
North America dominated the eltrombopag drugs market in 2023.
Growing research, cooperation from major industry participants, government backing, and investments in enhancing healthcare services are the reasons the area is leading. Continuous efforts are being made by all parties involved in the area to enhance the standard of care and available treatment choices. The U.S. and Canada are the two main nations that push the market forward. The number of disorders that need eltrombopag medications for therapy is increasing despite all the breakthroughs.
Chronic liver disease (CLD) is making rapid progress in the United States. At the moment, this disease ranks as the fourth leading cause of death for people aged 45 to 64. Each year, liver diseases such as cirrhosis, viral hepatitis, and liver cancer claim the lives of more than two million individuals. It also causes one out of every 25 deaths or 4% of all deaths worldwide; one out of every three liver-related deaths in women is caused by this condition. It has been estimated that 600,000 to 900,000 deaths are caused by liver cancer. Adults in the U.S., Europe, and Asia have experienced an increase in the prevalence of hepatitis A infection 69,70, mostly due to the higher frequency of person-to-person transmission among those who are homeless and battle with substance usage.
Asia Pacific is expected to grow at the fastest rate during the forecast period.
The eltrombopag drugs market is expanding rapidly in the Asia Pacific as a result of increased foreign investment and increased cooperation between different players. Because of its biggest population, the area has an advantage in terms of personnel. In an effort to establish a leading position globally and improve therapies in Asia Pacific, a number of market participants in the area are also engaged in research and development.
By type, the tablets segment held a significant share of the eltrombopag drugs market in 2023. Oral medication administration is the most popular method since it is easy to use, affordable, painless, has a high patient compliance rate, and offers a variety of dose forms. For a medicine to be administered orally, it must be significantly soluble in water, which results in increased bioavailability.
For instance,
By application, the hospitals and clinics segment held the major share of the eltrombopag drugs market in 2023. Hospital admission is necessary for the treatment and health monitoring of patients with acute myeloid leukemia, chronic liver illness, chronic immune thrombocytopenia, and other conditions. As a result, hospitals are the primary setting for TPO-RA usage. Hospitals are preferred by patients above other healthcare institutions because they have all the resources necessary to provide interdisciplinary treatment.
By Type
By Application
By Region
December 2024
December 2024
December 2024
December 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts